Baroreflex Activation Therapy for the Treatment of HFrEF – When CRT Is Not an Option
Published: 05 July 2021
-
Views:
737 -
Likes:
7
-
Views:
737 -
Likes:
7
-
2m 58sPart 1 Welcome and Introduction Jörn Schmitt , Faiez Zannad, Michael Knaut, Ainhoa Robles Mezcua
-
10m 21sPart 2 Introduction: BAT Mode of Action & Patient Indication for HF Jörn Schmitt
Overview
In this webinar, cardiologists, heart failure specialists and electrophysiologists will go through this simple implantable device that electrically stimulates the carotid baroreflex to improve symptoms of HFrEF. The panel will discuss patient indication, our latest clinical data, and incorporation into clinical practice.
Key Learning Objectives
- Review the role of the baroreflex as a primary regulator of cardiovascular function and have a better understanding of the mode of action.
- Identify the patient indication for carotid baroreceptor stimulation in heart failure with reduced ejection fraction.
- Review the long term data and experience with baroreflex activation therapy in heart failure with reduced ejection fraction.
- Get to know the device, and the implantation procedure of BAROSTIM.
- Exchange with experienced physicians that prescribe and use BAROSTIM in their hospitals.
Target Audience
- Heart Failure Specialist
- Cardiologist
- Interventional Cardiologist
- Rhythmologist
More from this programme
Part 1
Welcome and Introduction
1 session | |
Welcome and Introduction | Watch now |
Part 2
Introduction: BAT Mode of Action & Patient Indication for HF
Part 3
Clinical Results (Presentation of clinical data on Heart Failure as HOPE4HF & BeAT-HF study)
Part 4
Device Presentation & Implant Procedure
Part 5
Case Study: advanced HF, ventricular arrhythmias and BAROSTIM
Part 6
Summary of Baroreflex Activation Therapy for HFrEF
Faculty Biographies
Faiez Zannad
Professor of Therapeutics and Cardiology, Head of CIC
Prof Faiez Zannad is Professor of Therapeutics & Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU).
Prof Zannad is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension.
Prof Zannad is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.